Drugs / Minocycline
Minocycline
also known as
minocycline hydrochloride · minocycline HCL · Arestin · FMX-101 · FMX103 · BPX-04 · DFD-29 · FXFM244 · +18 more
Small molecule targets BDNF, MMP9 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed acne 1 milestone | |||||
| Filed | China (NMPA) | — | acne | 2023-09-26 | “the first topical minocycline to have its NDA accepted by the NMPA of the PRC.” cutiatx.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Label expansions (4) | US (FDA) | MINOCIN | — | 1975-03-21 – 1987-07-27 | fda.gov ↗ |
| Approved | US (FDA) | MINOCIN | — | 1971-06-30 | fda.gov ↗ |
Trials 200 · started per year
today
US approved 1971
1
1
2
2
6
2
1
4
5
2
5
13
7
13
15
11
7
15
16
6
6
5
6
11
13
7
6
9
1
1970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT07462702 | Oct 2026 → Aug 2027 expected | papillomatosis, confluent and reticulated | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07298057 | Feb 2026 → Jun 2027 expected | diabetes mellitus, noninsulin-dependent, 2, periodontitis | Case Western Reserve University | Recruiting | No outcome recorded |
| Phase 0 | NCT02998151 | Jan 2016 → Nov 2020 | fragile X syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 0 | NCT02362529 | Feb 2015 → Apr 2019 | major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 0 | NCT00881907 | Mar 2010 → Mar 2014 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT00881491 | Apr 2009 → Jan 2015 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT05605366 | Dec 2026 → Dec 2027 expected | cognitive disorder, cognitive impairment with or without cerebellar ataxia, sickle cell disease | University of Cincinnati | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06776445 | Jan 2024 → Jul 2025 | rosacea | First Affiliated Hospital of Chongqing Medical University | Completed | No outcome recorded |
| Phase 1 | NCT06997731 | May 2023 → Jan 2025 | chronic periodontitis | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 1 | NCT05630534 | Jan 2023 → Dec 2024 | intracerebral hemorrhage | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05597462 | Sep 2022 → May 2023 | rosacea | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02533232 | Aug → Dec 2022 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Unknown | No outcome recorded |
| Phase 1 | NCT05452785 | May 2022 | — | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05032781 | Jun 2021 → Sep 2024 | ischemic stroke | Northwell Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04031755 | Apr 2019 → Oct 2020 | autism | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT03291158 | Apr → Dec 2018 | — | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02808052 | May 2017 → Jun 2018 | acute kidney injury, chronic kidney disease | Melinta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02802631 | Apr 2017 → Feb 2018 | — | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03117530 | Apr 2017 → Dec 2022 | autism spectrum disorder | University of California, Los Angeles | Suspended | No outcome recorded |
| Phase 1 | NCT02201563 | Nov 2015 → May 2018 | radiation-induced disorder | University of Pittsburgh | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02515955 | Aug 2015 → Mar 2016 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02187211 | Jul 2015 → Nov 2018 | alcohol dependence | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02272270 | Oct 2014 → Mar 2017 | glioma | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT01976065 | Sep 2014 → Sep 2018 | dental pulp necrosis | Kenneth Hargreaves | Completed | No outcome recorded |
| Phase 1 | NCT02250859 | Sep → Dec 2014 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02178813 | Jul 2014 → Jul 2016 | stroke disorder | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 1 | NCT01574742 | Jun 2012 → Jun 2014 | depressive disorder | Shalvata Mental Health Center | Unknown | No outcome recorded |
| Phase 1 | NCT00630942 | Feb 2003 → May 2007 | primary sclerosing cholangitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/219 trials · 1 met primary · 1 missed | ||||||
| Phase 1/2 | NCT05474729 | Dec 2021 → Dec 2025 overdue | retinal degeneration, uveitis | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05680389 | Dec 2020 → Dec 2023 | cerebral amyloid angiopathy | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT05474950 | Jan 2019 → Jun 2024 | cystoid macular edema | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03050086 | Mar 2017 → Jun 2018 | rosacea | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02140164 | May 2014 → Nov 2015 | retinitis pigmentosa | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03040128 | Jun 2013 → Nov 2016 | intracerebral hemorrhage | University of Tennessee | Completed | No outcome recorded |
| Phase 1/2 | NCT01219673 | Mar 2013 → Jan 2014 | head and neck cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01805895 | Feb 2013 → Dec 2016 | intracerebral hemorrhage | Augusta University | Completed | No outcome recorded |
| Phase 1/2 | NCT01580969 | Jul 2012 → Jan 2018 | glioma | University of Utah | Completed | No outcome recorded |
| Phase 1/2 | NCT01468831 | Mar 2012 → Feb 2020 | occlusion of tributary of retinal vein | National Eye Institute (NEI) | Completed | Missed primary |
| Phase 1/2 | NCT01468844 | Dec 2011 → Mar 2015 | retinal vein occlusion | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01120899 | Apr 2010 → Aug 2011 | diabetic macular edema | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01058395 | Feb 2010 → Sep 2015 | traumatic brain injury | Wayne State University | Completed | Met primary |
| Phase 1/2 | NCT02113176 | Jan 2010 → Dec 2016 | acquired aneurysmal subarachnoid hemorrhage | University at Buffalo | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00630396 | May 2008 → Jan 2010 | stroke disorder | David Hess, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00559494 | Jun 2004 → Aug 2010 | spinal cord injury | University of Calgary | Completed | No outcome recorded |
| Phase 1/2 | NCT00029874 | Sep 2001 → Aug 2003 | Huntington disease | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 251 trials · 5 met primary · 8 missed | ||||||
| Phase 2 | NCT05367362 | Dec 2025 → Mar 2026 | ischemic stroke | State University of New York at Buffalo | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01422148 | Sep 2025 → Jan 2027 | atrial fibrillation | Baystate Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 2 | NCT06033846 | Oct 2023 → Jun 2024 | autoimmune encephalitis | Xijing Hospital | Completed | Missed primary |
| Phase 2 | NCT06207760 | Aug 2023 → Apr 2024 | depressive disorder | IRCCS Centro San Giovanni di Dio Fatebenefratelli | Unknown | No outcome recorded |
| Phase 2 | NCT05861258 | May 2023 → May 2025 | Mycobacterium avium complex disease | Radboud University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05077813 | Dec 2021 → Feb 2022 | tuberculosis | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04219735 | Jan 2020 → Nov 2021 | delirium | Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Completed | Met primary |
| Phase 2 | NCT04068207 | Aug 2019 → Jan 2023 | retinitis pigmentosa | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT04876638 | Jul 2019 → Dec 2027 expected | brain aneurysm, brain ischemia, intracranial vasospasm | University of Southern California | Active not recruiting | Met primary |
| Phase 2 | NCT03667222 | Sep 2018 → May 2019 | rosacea | BioPharmX, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03489629 | Apr 2018 → Sep 2025 | cystic fibrosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03106740 | Oct 2017 → Apr 2024 | chronic pain syndrome | Marco Loggia | Completed | Missed primary |
| Phase 2 | NCT03340961 | Oct 2017 → Nov 2018 | rosacea | Dr. Reddy's Laboratories Limited | Completed | Met primary |
| Phase 2 | NCT02946788 | Mar 2017 → Jun 2018 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02564978 | Dec 2016 → Sep 2022 | age-related macular degeneration | National Eye Institute (NEI) | Completed | Missed primary |
| Phase 2 | NCT02815332 | Aug 2016 → Mar 2017 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02709096 | Apr → Jun 2016 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02213575 | Mar 2016 → Nov 2018 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02680379 | Mar 2016 → Oct 2017 | fragile X syndrome | University of Sherbrooke | Completed | No outcome recorded |
| Phase 2 | NCT02203552 | Jun 2015 → Jun 2020 | anxiety disorder, depressive disorder, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02456948 | Jan 2015 → Aug 2020 | major depressive disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT02297412 | Nov 2014 → Jul 2016 | breast carcinoma, peripheral neuropathy | Academic and Community Cancer Research United | Completed | Mixed |
| Phase 2 | NCT02133872 | Oct 2014 → Nov 2018 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02055963 | May 2014 → Aug 2022 | head and neck cancer | M.D. Anderson Cancer Center | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02056665 | Jan → Sep 2014 | Angelman syndrome | Puerta de Hierro University Hospital | Completed | Missed primary |
| Phase 2 | NCT01906008 | Nov 2013 → Feb 2019 | colorectal cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01809340 | Jun 2013 → Jul 2014 | depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01539343 | Apr 2013 → Apr 2016 | infectious disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01793051 | Mar 2013 → Sep 2020 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02928965 | Feb 2013 → May 2016 | schizophrenia | University of Manchester | Completed | No outcome recorded |
| Phase 2 | NCT01746043 | Feb 2013 → Jan 2017 | esophageal cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01693523 | Jan 2013 → Sep 2018 | malignant pancreatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01636934 | Jul 2012 → Sep 2019 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01695291 | May 2012 → May 2017 | obsessive-compulsive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT01362010 | Jan 2012 → Jun 2013 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02051296 | Jan 2012 → Apr 2014 | chronic pain syndrome | VA Palo Alto Health Care System | Completed | No outcome recorded |
| Phase 2 | NCT01349192 | Apr 2011 → Jan 2015 | cystic fibrosis, methicillin-resistant staphylococcus aureus infectious disease | University of North Carolina, Chapel Hill | Terminated | Met primary Stop: Enrollment |
| Phase 2 | NCT01283997 | Jan 2011 → Aug 2022 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | Missed primary |
| Phase 2 | NCT01314482 | Nov 2010 → Dec 2013 | — | University of Adelaide | Unknown | No outcome recorded |
| Phase 2 | NCT01171326 | Aug 2010 → Mar 2012 | impetigo | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01173692 | Jul 2010 → Jul 2020 | oropharynx cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01134991 | Jun 2010 → Mar 2014 | rosacea | Vyne Therapeutics Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | Missed primary |
| Phase 2 | NCT00515255 | Jul 2007 → Apr 2008 | obsessive-compulsive disorder | Neuropharm | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00361257 | Mar 2007 → Jan 2010 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | Missed primary |
| Phase 2 | NCT00355576 | Jul 2006 → May 2007 | amyotrophic lateral sclerosis | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT01134627 | Feb 2006 → Apr 2011 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT00063193 | May 2003 → May 2005 | Parkinson disease | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00536042 | Oct 1997 → Jun 2009 | asthma | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00456677 | Jun 1996 → Oct 2007 | asthma | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT07594314 | May 2026 → Dec 2028 expected | brain infarction, ischemic stroke, vascular occlusion disorder | Xiang Luo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07594301 | May 2026 → Dec 2028 expected | arterial occlusion, ischemic stroke | Xiang Luo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07237048 | Feb 2026 → Dec 2028 expected | intracerebral hemorrhage, ischemic stroke | Joyce Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06255067 | Feb → May 2024 | periodontitis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06107725 | Nov 2023 → May 2024 | hemorrhagic stroke, ischemic stroke | Maimonides Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04319575 | Dec 2018 → Apr 2020 | suppurative periapical periodontitis | Dr. D. Y. Patil Dental College & Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03320018 | Aug 2017 → Aug 2019 | ischemic stroke | Stony Brook University | Completed | No outcome recorded |
| Phase 2/3 | NCT01813240 | May 2013 → Apr 2015 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2/3 | NCT00277355 | Apr 2006 → Oct 2008 | Huntington disease | Merit Cudkowicz | Completed | No outcome recorded |
| Phase 329 trials · 4 met primary · 2 missed | ||||||
| Phase 3 | NCT07526987 | Jun 2026 → Dec 2028 expected | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07338175 | Apr 2026 → Jun 2028 expected | intracerebral hemorrhage | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07082855 | Jul 2025 → Feb 2028 expected | retinitis pigmentosa | Zhongshan Ophthalmic Center, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05296629 | Mar 2022 → Jun 2023 | rosacea | Journey Medical Corporation | Completed | Met primary |
| Phase 3 | NCT04960930 | Sep 2021 → Sep 2022 | acne | Cutia Therapeutics (Shanghai) Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04291456 | Jan 2020 → Dec 2022 | multiple sclerosis | University of Calgary | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03276936 | Sep 2017 → Jan 2019 | rosacea | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03271021 | Jul 2017 → Sep 2018 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03142451 | Jun 2017 → Aug 2018 | rosacea | Vyne Therapeutics Inc. | Completed | Met primary |
| Phase 3 | NCT04608500 | Jun 2017 → Jul 2018 | rosacea | Vyne Therapeutics Inc. | Completed | Met primary |
| Phase 3 | NCT04547764 | Jun 2017 → Dec 2018 | dental pulp disorder | King Abdulaziz University | Completed | No outcome recorded |
| Phase 3 | NCT02928692 | Nov 2016 → Dec 2021 | colon carcinoma, prostate cancer, rectal carcinoma, renal carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02703363 | Aug 2016 → Dec 2018 | bipolar depression | Pakistan Institute of Living and Learning | Completed | Missed primary |
| Phase 3 | NCT02815267 | May 2016 → Oct 2017 | acne | Vyne Therapeutics Inc. | Completed | Mixed |
| Phase 3 | NCT02815280 | May 2016 → Oct 2017 | acne | Vyne Therapeutics Inc. | Completed | Met primary |
| Phase 3 | NCT01828203 | Jun 2013 → Jun 2018 | spinal cord injury | Rick Hansen Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02541500 | Apr 2013 → Jan 2017 | amphetamine abuse, heroin dependence | Universiti Sains Malaysia | Unknown | No outcome recorded |
| Phase 3 | NCT01517334 | May 2012 → Sep 2014 | periodontal disorder | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT01539564 | Apr 2012 → May 2014 | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT01403662 | Jul 2011 → Feb 2014 | bipolar depression | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT01083420 | Mar 2010 → Mar 2011 | lichen planus, oral | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00662532 | Apr 2008 → Apr 2009 | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT00392223 | Oct 2007 → Jun 2008 | acne | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00371332 | Jan 2004 → ? | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT00146809 | Dec 2003 → Dec 2005 | multiple system atrophy | German Parkinson Study Group (GPS) | Completed | No outcome recorded |
| Phase 3 | NCT00733057 | Aug 2003 → Mar 2007 | — | Shalvata Mental Health Center | Completed | No outcome recorded |
| Phase 3 | NCT00047723 | Jan 2003 → Jan 2007 | amyotrophic lateral sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | Missed primary |
| Phase 3 | NCT00154895 | Jun 2001 → Mar 2005 | pneumothorax | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00203697 | — | idiopathic pulmonary fibrosis | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 439 trials · 2 met primary · 3 missed | ||||||
| Phase 4 | NCT06699966 | Jun 2027 → Jun 2031 expected | major depressive disorder | Stony Brook University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07068607 | Apr → Oct 2025 overdue | Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 | Yongquan Shi | Recruiting | Missed primary |
| Phase 4 | NCT06246396 | Jan 2025 → Jul 2028 expected | resistant hypertension | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06523764 | Nov 2024 → Aug 2025 overdue | chronic gastritis | Xijing Hospital of Digestive Diseases | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06561711 | Aug 2024 → Feb 2026 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT06561698 | Aug 2024 → Aug 2026 overdue | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06603688 | Nov 2023 → Nov 2024 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Phase 4 | NCT06307288 | Oct 2023 → Jun 2024 | rosacea | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT05512910 | Mar 2023 → Mar 2025 overdue | basilar artery occlusion, ischemic stroke | Xijing Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05586815 | Jan 2023 → Jan 2024 | Acinetobacter infectious disease | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT05575427 | Nov 2022 → Jul 2024 | nosocomial infection | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT05487417 | Nov 2022 → Jun 2025 overdue | ischemic stroke | Xijing Hospital | Recruiting | Missed primary |
| Phase 4 | NCT06818578 | Sep 2022 → Aug 2024 | dental pulp necrosis, pulpitis, teeth present at birth | Inonu University | Completed | No outcome recorded |
| Phase 4 | NCT06044090 | Sep 2022 → Dec 2023 | — | University of North Carolina, Chapel Hill | Completed | Missed primary |
| Phase 4 | NCT04558502 | Jan → Jun 2022 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04940767 | Jun 2021 → Apr 2023 | acne | Edward Lain, MD | Completed | No outcome recorded |
| Phase 4 | NCT04531059 | Oct 2020 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03762915 | May 2019 → Apr 2022 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT04076098 | Jun 2018 → Dec 2020 | periodontitis | Mahsa University | Completed | No outcome recorded |
| Phase 4 | NCT03369951 | Mar 2018 → Jul 2019 | bacterial infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT03340350 | May 2017 → Jun 2018 | post-traumatic stress disorder | Sriram Ramaswamy | Completed | No outcome recorded |
| Phase 4 | NCT02968602 | Mar 2017 → Jul 2019 | nicotine dependence, schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT04036890 | Jun 2016 → Oct 2019 | periodontitis | National Dental Centre, Singapore | Completed | No outcome recorded |
| Phase 4 | NCT02695446 | Mar → Apr 2016 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02712775 | Mar 2016 | liver disorder | Medical University of South Carolina | Withdrawn | No outcome recorded |
| Phase 4 | NCT02124811 | Feb 2015 → Nov 2016 | schizoaffective disorder, schizophrenia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02263872 | Oct 2014 → Jun 2016 | major depressive disorder | Pakistan Institute of Living and Learning | Completed | Met primary |
| Phase 4 | NCT02618317 | Jul 2013 → Feb 2016 | chronic kidney disease | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02355977 | Jun 2013 → Sep 2014 | chronic periodontitis | Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT01647282 | Oct 2012 → Dec 2015 | chronic periodontitis | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT01514422 | May 2011 → Aug 2013 | bipolar depression | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT01206348 | Sep 2010 → Jul 2011 | acne | Medicis Global Service Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01133080 | Jun 2010 → Jan 2013 | schizophrenia | Shalvata Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT05014906 | May 2010 → Sep 2011 | rosacea | Dermatology Specialists Research | Completed | No outcome recorded |
| Phase 4 | NCT00988026 | Jun 2009 → Feb 2010 | adult acne | Darier | Unknown | No outcome recorded |
| Phase 4 | NCT00668746 | Dec 2007 → Feb 2009 | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 4 | NCT00409747 | Nov 2006 → Jun 2010 | autism | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00294502 | Sep 2003 → May 2004 | end stage renal failure | Henry Ford Health System | Completed | Met primary |
| Phase 4 | NCT00145106 | Mar → Aug 2002 | acne | KGL, Inc. | Completed | No outcome recorded |
| Phase not applicable25 trials · 1 met primary · 1 missed | ||||||
| — | NCT07239739 | Jun → Nov 2026 expected | periapical periodontitis | Faiz ur rahman | Not yet recruiting | No outcome recorded |
| — | NCT07305896 | Dec 2025 → Dec 2028 expected | intracerebral hemorrhage | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| — | NCT06537921 | Oct 2024 → Sep 2027 expected | major depressive disorder, obesity disorder | King's College London | Recruiting | No outcome recorded |
| — | NCT06004401 | Aug 2023 → Aug 2025 | — | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT05902819 | May 2023 → Mar 2026 | post-traumatic stress disorder, substance-related disorder | Psychiatric University Hospital, Zurich | Completed | No outcome recorded |
| — | NCT05958069 | Mar 2023 → Mar 2024 | epilepsy | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT06027151 | Oct 2022 → Jul 2023 | diabetes mellitus, periodontitis | Riphah International University | Completed | No outcome recorded |
| — | NCT07804979 | May 2022 → Jun 2023 | major depressive disorder | Lahore General Hospital | Completed | No outcome recorded |
| — | NCT04923113 | Jun 2021 → Jan 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT04433143 | May 2020 → May 2021 | acne | Gang Wang | Unknown | No outcome recorded |
| — | NCT04125706 | Nov 2019 → Jul 2020 | periodontitis | Riyadh Elm University | Unknown | No outcome recorded |
| — | NCT03768557 | Apr 2017 → Oct 2018 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT02765100 | Oct 2014 → Oct 2019 | bipolar disorder, depressive disorder, obesity disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT01531582 | Apr 2012 → Dec 2014 | Angelman syndrome | University of South Florida | Completed | No outcome recorded |
| — | NCT01659320 | Mar 2012 → Apr 2015 | depressive disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT01561742 | Feb 2012 → Jan 2015 | schizophrenia | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
| — | NCT01600625 | Nov 2011 → Jul 2012 | eye adnexa disorder | Yonsei University | Completed | No outcome recorded |
| — | NCT01317550 | Jul 2011 → Feb 2016 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT01053156 | Jan 2010 → Dec 2011 | fragile X syndrome | University of California, Davis | Completed | No outcome recorded |
| — | NCT00836355 | Apr → Dec 2009 | ischemic stroke | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01779089 | Feb 2009 → Mar 2016 | diabetic kidney disease | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Unknown | Missed primary |
| — | NCT00858689 | Oct 2007 → Nov 2008 | fragile X syndrome | FRAXA Research Foundation | Completed | Met primary |
| — | NCT00355459 | Aug 2005 → Apr 2007 | dry eye syndrome | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| — | NCT00777413 | Nov 2002 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT00378781 | — | cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Comparator or background therapy64 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04210713 Comparator | Feb 2020 → Sep 2023 | alcohol dependence, cognitive disorder, mental disorder | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02947763 Comparator | Nov 2016 → Jan 2018 | periapical periodontitis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT02193269 Comparator | Jul 2013 → Nov 2015 | cognitive impairment with or without cerebellar ataxia | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00243893 Comparator | Jul 2004 → Oct 2008 | arteriovenous malformations of the brain, brain aneurysm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT06889701 Background | Apr 2025 → Aug 2026 overdue | periprosthetic joint infection | TenNor Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02133885 Comparator | Jan 2023 → Mar 2024 | hypertensive disorder | University of Florida | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04594733 Comparator | Dec 2021 → Aug 2022 | fibromyalgia | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT03244592 Comparator | Jan → Mar 2018 | alcohol-related disorders, cognitive disorder | University of California, Los Angeles | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02060149 Background | Mar 2014 → Mar 2015 | pneumonia | Xijing Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00855062 Comparator | Apr 2008 → Dec 2009 | HIV infectious disease, cognitive impairment with or without cerebellar ataxia | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00916461 Comparator | May 2006 → Mar 2008 | schizophrenia | Stanley Medical Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01048983 Comparator | — | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT07858916 Background | Oct 2026 → Sep 2027 expected | periprosthetic joint infection | TenNor Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05826912 Comparator | Aug 2024 → Aug 2028 expected | traumatic brain injury | University of California, San Francisco | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06201793 Comparator | Jan 2024 → Jan 2025 | inflammatory bowel disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2 | NCT04202263 Comparator | Sep 2019 → Sep 2023 | allergic rhinitis, asthma | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04104685 Comparator | Sep 2019 → Feb 2020 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03888378 Comparator | Apr 2019 → Sep 2020 | eye adnexa disorder | Hovione Scientia Limited | Completed | No outcome recorded |
| Phase 2 | NCT03964935 Comparator | Dec 2018 → Aug 2019 | periodontal disorder | University of Baghdad | Unknown | No outcome recorded |
| Phase 2 | NCT03263273 Comparator | Oct 2017 → Mar 2019 | rosacea | Hovione Scientia Limited | Completed | No outcome recorded |
| Phase 2 | NCT02569307 Comparator | Oct 2015 → Dec 2018 | psychotic disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 2 | NCT01463384 Comparator | Sep 2011 → Oct 2012 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Huntington Medical Research Institutes | Completed | No outcome recorded |
| Phase 2 | NCT01297816 Comparator | Dec 2010 | retinal detachment | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01073813 Comparator | Feb 2010 → Dec 2011 | multiple sclerosis, optic neuritis | University of Calgary | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00401921 Comparator | Oct 2006 → Jun 2010 | carotid stenosis | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00203112 Comparator | Jun 2004 → Jun 2006 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT06821763 Comparator | May → Oct 2025 overdue | periodontitis, pulpitis | Komal Ashraf Khan | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05836740 Comparator | May 2023 → May 2024 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04478500 Comparator | Jul 2020 → Aug 2024 | resistant hypertension | Royal Perth Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03947827 Comparator | Feb 2020 → Jan 2025 | — | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 3 | NCT02541032 Comparator | Dec 2015 → Jun 2019 | periodontal disorder, transient ischemic attack | University of South Carolina | Unknown | No outcome recorded |
| Phase 3 | NCT02907437 Comparator | Jan 2015 → Feb 2017 | schizophrenia | Beer Yaakov - Ness Ziona Mental Health Center | Unknown | No outcome recorded |
| Phase 3 | NCT01931150 Background | Aug 2013 → Sep 2015 | acneiform dermatitis, cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01429272 Comparator | Sep 2011 → Aug 2015 | bipolar depression | Laureate Institute for Brain Research, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01320982 Comparator | Mar 2011 → Jun 2012 | schizoaffective disorder, schizophrenia | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00666887 Comparator | Jan 2009 → Dec 2014 | multiple sclerosis | Dr. Luanne Metz | Completed | No outcome recorded |
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 3 | NCT00529555 Comparator | Jan 2006 → Dec 2008 | periodontitis, chronic, adult | Sunstar Americas | Completed | No outcome recorded |
| Phase 3 | NCT00579644 Comparator | Mar 2001 → May 2006 | rheumatoid arthritis | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT07405697 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405684 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07437209 Comparator | Dec 2024 → Dec 2025 | periodontitis, aggressive | Center for Advanced Rejuvenation and Esthetics | Completed | No outcome recorded |
| Phase 4 | NCT05530252 Comparator | Sep → Dec 2022 | periodontitis | Beijing Stomatological Hospital, Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT04020588 Comparator | Feb 2019 → Jun 2020 | schizophrenia | Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT02719392 Comparator | Aug 2017 → Jun 2026 | bipolar depression | Massachusetts General Hospital | Suspended | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02913118 Background | Jul 2016 → Jan 2019 | — | Qingfeng Pharmaceutical Group | Unknown | No outcome recorded |
| Phase 4 | NCT01809158 Comparator | Apr 2013 → May 2016 | schizophrenia | Addis Ababa University | Completed | No outcome recorded |
| Phase 4 | NCT01869907 Comparator | Sep 2011 → Aug 2014 | radiculopathy | Ziekenhuis Oost-Limburg | Completed | No outcome recorded |
| Phase 4 | NCT01313208 Background | Mar 2011 → Feb 2013 | rheumatoid arthritis | Amgen | Completed | Missed primary |
| Phase 4 | NCT01493622 Comparator | Jun 2010 → Nov 2011 | schizophrenia | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02030912 Comparator | Dec 2009 → Dec 2012 | — | Helperby Therapeutics Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00930020 Comparator | Jul 2009 → Jul 2012 | stroke disorder | Singhealth Foundation | Terminated | No outcome recorded |
| Phase 4 | NCT00765336 Comparator | Nov 2006 → Dec 2008 | — | Medicis Pharmaceutical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00240513 Comparator | Aug 2004 → Dec 2006 | acne | Derm Research @ 888 Inc. | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03763110 Comparator | Oct 2016 → Dec 2018 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT02359006 Comparator | Mar 2015 → Apr 2017 | opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT01802216 Comparator | Feb 2014 → Sep 2017 | chronic kidney disease, periodontal disorder | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01433055 Comparator | Jul 2011 → Jan 2014 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT03507556 Background | Jun 2010 → Nov 2021 overdue | — | Jordan University of Science and Technology | Active not recruiting | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
| — | NCT00556491 Comparator | Dec 2007 → Jul 2011 | acute kidney injury | Tarek M. El-Achkar | Completed | No outcome recorded |
| — | NCT01049438 Background | Aug 2006 → Sep 2009 | methicillin-resistant staphylococcus aureus infectious disease | Natividad Medical Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 21
| Date | Issuer | Release |
|---|---|---|
| 2025-12-10 | Journey Medical Corporation | Results Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology journeymedicalcorp.com ↗
The results indicate that DFD-29 administration for 16 weeks had no detectable effects on skin, GI tract or vaginal microflora and it was well tolerated in healthy adults, supporting its use as a therapeutic option for patients with moderate-to-severe rosacea. |
| 2025-10-24 | Journey Medical Corporation | Results Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference journeymedicalcorp.com ↗
DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P<0.001 for all comparisons) |
| 2025-06-20 | Journey Medical Corporation | Results Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference journeymedicalcorp.com ↗
The analysis determined that differences in body weight did not affect the efficacy of Emrosi in the two Phase 3 trials, which supported its November 2024 FDA approval. |
| 2025-03-05 | Journey Medical Corporation | Results Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea journeymedicalcorp.com ↗
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks |
| 2024-11-11 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT -
CU-10201 (TOPICAL 4% MINOCYCLINE FOAM)
OBTAINED MARKETING APPROVAL BY THE NATIONAL
MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that CU-10201 (topical 4% minocycline foam) of the Group has obtained marketing approval by the National Medical Products Administration (the “NMPA”) of the People ’s Republic of China (the “PRC”). |
| 2024-11-04 | Journey Medical Corporation | Regulatory Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea journeymedicalcorp.com ↗
today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. |
| 2024-07-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED ONLINE IN THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY cutiatx.com ↗
RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED ONLINE IN THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY |
| 2024-05-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF
CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PRESENTED AT THE 13TH ADC cutiatx.com ↗
RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PRESENTED AT THE 13TH ADC |
| 2024-03-18 | Journey Medical Corporation | Regulatory Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea journeymedicalcorp.com ↗ |
| 2024-03-11 | Journey Medical Corporation | Results Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting journeymedicalcorp.com ↗
Results indicate that DFD-29 can be safely used for up to 16 weeks with no detectable effects on microbiota in the skin, GI tract, or vagina |
| 2024-01-05 | Journey Medical Corporation | Regulatory Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea journeymedicalcorp.com ↗
today announced that the Company has submitted a New Drug Application (“NDA”) to the FDA seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. |
| 2023-12-11 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIALS OF
CU-40102 (TOPICAL FINASTERIDE SPRAY) AND
CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC
PUBLISHED AT THE 18TH CDA ANNUAL MEETING cutiatx.com ↗
RESULTS OF PHASE III CLINICAL TRIALS OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED AT THE 18TH CDA ANNUAL MEETING |
| 2023-10-20 | Journey Medical Corporation | Results Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) journeymedicalcorp.com ↗
The results of this bioavailability study successfully demonstrate that the systemic exposure of minocycline with DFD-29 (40 mg) was significantly lower than that of Solodyn (105 mg),” said Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. |
| 2023-09-26 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that the New Drug Application (the “NDA”) for CU-10201 was accepted by the NMPA of the PRC. |
| 2023-08-10 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) HAS BEEN GRANTED PRIORITY REVIEW DESIGNATION BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗ |
| 2023-07-11 | Journey Medical Corporation | Results Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults journeymedicalcorp.com ↗
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues |
| 2023-06-19 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg (USRLD: Solodyn Tablets, 55 mg, 65 mg, and 115 mg). |
| 2023-06-13 | Journey Medical Corporation | Results Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects journeymedicalcorp.com ↗
The study achieved all primary objectives and no significant safety issues were noted during the study. |
| 2022-12-20 | Journey Medical Corporation | Results Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29 journeymedicalcorp.com ↗
The study successfully demonstrated that the systemic exposure of DFD-29 (40 mg) was significantly lower than that of SOLODYN (105 mg). |
| 2009-03-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval and Launch of Generic Solodyn® Extended-Release Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Medicis Pharmaceutical Corporation's acne treatment Solodyn® (Minocycline HCl) Extended-Release Tablets, 45 mg, 90 mg and 135 mg. |
| 2009-02-05 | Impax Laboratories, LLC | Regulatory IMPAX Receives Final FDA Approval for Generic SOLODYN Extended-Release Tablets, 45mg, 90mg and 135mg amneal.com ↗
IMPAX Laboratories, Inc. (OTC: IPXL) today confirmed that the U.S. Food and Drug Administration ( FDA ) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic versions of SOLODYN(R) (minocycline HCI) 45mg, 90mg and 135mg Extended-release Tablets. |
All press releases naming this drug 42 releases
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 266 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Minocycline | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗256“Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland...” NCT00355459 ↗ “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “Minocycline hydrochloride capsules: administered orally twice daily; the first dose is 200 mg (2 capsules), and all subsequent doses are 100 mg (1 capsule), for 56-63 days.” NCT07858916 ↗ “The TAP was freshly prepared and proportioned in equal parts by volume (metronidazole, minocycline, and ciprofloxacin=1:1:1) before the scheduled treatment appointment.” NCT04547764 ↗ “mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.” NCT06821763 ↗ “Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation” NCT03763110 ↗ “ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.” NCT00881907 ↗ “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019” NCT04940767 ↗ |
| Known as | AMZEEQ | “topical minocycline foam (AMZEEQ®)” NCT07462702 ↗ |
| Known as | Arestin | “The aim of this randomised pilot clinical trial was to determine if type 1 diabetes patients with periodontitis will experience a reduction in HbA1c levels when treated with...” PMID 15536785 ↗ Oct 20043“This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride...” NCT07437209 ↗ |
| Known as | Arestin (minocycline microspheres) 1 mg | “Arestin (minocycline microspheres) 1 mg” NCT01647282 ↗ |
| Known as | Borymycin | “Minocycline (Borymycin)” NCT00930020 ↗ |
| Known as | BPX-01 | “BPX-01 Minocycline 1% Topical Gel (BPX-01)” NCT02709096 ↗ |
| Known as | BPX-04 | “Drug: BPX-04 1% minocycline topical gel” NCT03050086 ↗1“BPX-04 minocycline topical gel” NCT03667222 ↗ |
| Known as | DFD-29 | “Treatment-A: A single 40 mg dose of DFD-29 (Minocycline Hydrochloride) (1 × 40 mg Extended-Release capsule) administered following a 10-hour overnight fast” NCT05452785 ↗1“We assessed the efficacy, safety, and dose response of DFD-29, a minocycline extended-release oral capsule.” PMID 35096250 ↗ Dec 2021 |
| Known as | doxycycline | “Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).” NCT02060149 ↗ |
| Known as | Dynacin | “Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules.” NCT01433055 ↗ |
| Known as | FMX-101 | “This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of...” NCT02815280 ↗3“daily dose of topical FMX-101 minocycline (4%) foam for sixteen consecutive days” NCT02250859 ↗ “FMX-101, 4% minocycline foam applied topically once daily for 12 weeks” NCT02815267 ↗ “FMX101 4% minocycline foam” NCT04960930 ↗ |
| Known as | FMX103 | “Subjects who elect to continue into this open-label study will receive supplies of active FMX103 1.5% minocycline foam.” NCT03276936 ↗ |
| Known as | FXFM244 | “This is a pilot phase II study to evaluate the tolerability and safety and to monitor the clinical efficacy of Topical Minocycline Foam FXFM244 in moderate to severe Rosacea patients.” NCT01134991 ↗1“Topical Minocycline Foam FXFM244” NCT07462702 ↗ |
| Known as | MINO | “whether minocycline (MINO), an FDA-approved antibiotic medication, affects any of the above listed measures” NCT04210713 ↗ |
| Known as | Minocin | “The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland...” NCT00355459 ↗1“Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment” NCT01600625 ↗ |
| Known as | Minocycline (generic name) | “Minocycline (generic name)” NCT02178813 ↗ |
| Known as | minocycline extended release | “Drug: minocycline extended release” NCT00765336 ↗ |
| Known as | Minocycline Extended-Release Tablets | “The study will include Minocycline Extended-Release Tablets, a new once-daily formulation of minocycline, compared with a placebo or inactive pill.” NCT00765336 ↗ |
| Known as | minocycline HCL | “DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.” NCT03340961 ↗5“Minocycline HCl 2.1% gel as an adjunct to scaling and root planing.” NCT00529555 ↗ “Minocycline HCl Microspheres, 1mg minocycline powder per cartridge.” NCT03964935 ↗ “1 mg/kg extended release minocycline HCL, once daily for 84 days.” NCT00765336 ↗ “locally-applied minocycline HCl (1 mg)” NCT01647282 ↗ |
| Known as | Minocycline HCL Extended-Release Tablets | “Solodyn (Minocycline HCL Extended-Release Tablets)” NCT01206348 ↗ |
| Known as | minocycline hydrochloride | “The experimental group will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical therapy after randomization, followed by 100 mg...” NCT07305896 ↗10“Minocycline hydrochloride capsules: 100 mg/capsule. Administered orally q12h ± 1h daily, doubling the first dose, 200 mg (2 capsules) orally, then 100 mg (1 capsule) each time...” NCT06889701 ↗ “The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days.” NCT05367362 ↗ “Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.” NCT05597462 ↗ “50 mg per capsule, containing 50mg of Minocycline Hydrochloride” NCT07338175 ↗ “2% minocycline hydrochloride controlled-delivery system (MHS)” NCT04036890 ↗ |
| Known as | Minocycline hydrochloride (HCL) | “Clinical parameters bleeding on probing (BOP), pocket depth (PD), and clinical attachment level (CAL) have been improved when Minocycline hydrochloride (HCL) microspheres was...” NCT03964935 ↗ |
| Known as | minocycline microspheres hydrochloride | “This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride...” NCT07437209 ↗ |
| Known as | Minoz | “minocycline (Minoz, 100 mg, Ranbaxy, India)” NCT06818578 ↗ |
| Known as | Mirocin | “In the minocycline group, 20 mL of 2% lidocaine hydrochloride (400mg) followed by a solution of 20 mL of normal saline containing 300 or 400 mg (7mg/kg) of minocycline...” NCT00154895 ↗ |
| Known as | Periocline | “active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan)” NCT04036890 ↗ |
| Known as | Solodyn | “Solodyn (Minocycline HCL Extended-Release Tablets)” NCT01206348 ↗1“Solodyn (Minocycline) Fasting” NCT05452785 ↗ |
| Action | Inhibit | “inhibits caspase-1 and caspase-3 expression” NCT00029874 ↗ |
| Modality | Small molecule | “Minocycline-a medication currently approved by the FDA for treatment of bacterial infections-is a tetracycline antibiotic with high central nervous system penetration when taken orally.” NCT00047723 ↗ |
| Route | Oral | “when taken orally” NCT00047723 ↗ |
| Target | MMP9 | “it lowers matrix metalloproteinase 9 (MMP9) levels” NCT01053156 ↗ |